Blood · 1995 · 84 citations · 27 references
PharmacyPharmacokineticsPharmacologyImmunopharmacologyImmunotherapyMonoclonal AntibodiesAntibody CharacterizationAntibody PharmacokineticsMonoclonal Antibody TherapyPharmacokinetics Of ImmunotherapiesPharmacokinetics Of Monoclonal AntibodiesTherapeutic Monoclonal AntibodiesAdministration Of Monoclonal AntibodiesInterleukin-6 InhibitionInterleukin-6 InhibitorsMonoclonal Antibody InfusionMonoclonal Antibody TherapeuticsPharmacokinetic Study DesignPharmacokinetic Targeting
The use of inhibiting cytokine-binding-proteins (CBPs) such as soluble cytokine receptors and anticytokine antibodies is considered for the treatment of cytokine-dependent diseases. The pleiotropic cytokine interleukin-6 (IL-6) is a target for immunointervention in numerous pathologic situations, including multiple myeloma, B-cell lymphoma, and rheumatoid arthritis. An antitumor response was obtained in the treatment of a patient with multiple myeloma. A controversial issue is to evaluate whether the carrier effect of the CBPs might limit their efficiency in blocking the target cytokine. We analyzed the pharmacokinetics of radiolabeled IL-6 in mice treated with various combinations of anti-IL-6 antibodies. We show that injection of one or two antibodies led to the stabilization of the cytokine. Conversely, simultaneous treatment with three anti-IL-6 antibodies, binding to three distinct epitopes, induced the rapid uptake of the trimeric immune complexes by the liver and the elimination of IL-6 from the central compartment. The use of cocktails of three antibodies binding simultaneously to a cytokine thus provides a new means of enhancing the clearance of the target molecule and should help in the design of antibody-based clinical trials by overcoming the problem of the accumulation of the cytokine in the form of monomeric immune complexes.
27
Tadamitsu Kishimoto · Blood · 1989 · 1.9K citations
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Michio Kawano, Toshio Hirano, Tadashi Matsuda et al. · Nature · 1988 · 1.7K citations
Medicine, Immunology, Oncology +11
Increased Osteoclast Development After Estrogen Loss: Mediation by Interleukin-6
Robert L. Jilka, Giao Hangoc, Giuseppe Girasole et al. · Science · 1992 · 1.5K citations
Medicine, Endocrinology, Immunology +17
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Bernard Klein, John Wijdenes, XG Zhang et al. · Blood · 1991 · 412 citations · Full text
Medicine, Hematology, Oncology +14